StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SBC$3.21-0.78%
Fair $3.21+0.0%

SBC

SBC Medical Group Holdings Incorporated

Industrials / Consulting ServicesNasdaqGM

$3.21

-0.03 (-0.78%)

Fairly Valued+0.0%Fair Value $3.21Fund rank 29/100 · Data gapFallback financials|
SA 50/C
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 21%

FCF escenarios

weak_data · normalized FCF $22.0M · quality 48.7/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 27/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

50/100

C

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists.
Thesis & Journal · SBCLocal privado en este navegador · SBC Medical Group Holdings Incorporated
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$329M

P/E

8.0x

↓

EV/EBITDA

2.5x

↓

ROE

20.5%

↑

Gross Margin

73.3%

↑

Debt/Equity

0.21

↓
52-Week Range$3
$3$6

TradingView lightweight chart

SBC price, volumen y niveles de valoración

Último $3.185Periodo -68.0%
Fair value: $3.210

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-0.1%

FCF CAGR

—

FCF margin

12.7%

FCF / Net income

0.43x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $173.6M · net income $51.0M · FCF $22.0M

2022-FY → 2025-FY

Gross margin

73.3%+7.4% pts

Operating margin

38.9%+26.6% pts

Net margin

29.4%+25.7% pts

FCF margin

12.7%+27.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$173.6M$173.6M$205.4M$193.5M$174.2M
Net Income$51.0M$51.0M$46.6M$39.4M$6.3M
EBITDA$84.9M$84.9M$77.3M$85.9M$29.6M
EPS0.500.500.480.390.06
Gross Margin73.3%73.3%76.0%70.9%65.9%
Operating Margin38.9%38.9%41.6%36.7%12.3%
Net Margin29.4%29.4%22.7%20.3%3.6%
Balance Sheet
Debt/Equity0.210.210.060.160.15
Current Ratio3.823.82———
Cash Flow
Free Cash Flow$22.0M$22.0M$17.2M$39.5M$-25.0M
Returns
ROE20.5%20.5%23.9%27.7%6.0%
Valuation
P/E7.967.9611.7127.51163.36
EV/EBITDA2.542.545.5611.6833.60
P/B1.321.322.787.629.80
Growth & Yield
Revenue Growth-15.5%-15.5%6.1%11.1%—
EPS Growth4.2%4.2%22.8%523.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-17.1%

fácil

EPS terminal req.

$0.28

Spread vs growth

21.3%

5Y implied EPS CAGR

-7.2%

fácil

EPS terminal req.

$0.34

Spread vs growth

11.3%

10Y implied EPS CAGR

1.1%

fácil

EPS terminal req.

$0.56

Spread vs growth

3.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -31.9%

Total return

-31.9%

Start / end P/E

9.7x → 6.4x

EPS bridge

0.48 → 0.50

Residual

-1.4%

EPS growth+4.2%
Multiple rerating-34.6%
Dividend+0.0%
Residual / FX / buybacks / cross-term-1.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.